Jefferies Raises LLY Price Target to $1,350, Reaffirms Buy as Stock Nears 52-Week High
By TrendSpider Editor
Jefferies analyst Akash Tewari has reaffirmed a Buy rating on Eli Lilly and Company while lifting the price target from $1,330 to $1,350, signaling continued conviction in the pharma giant's growth trajectory. LLY shares are currently trading at $1,163.01, up 2.32% on the session, and sitting close
Jefferies Raises LLY Price Target to $1,350, Reaffirms Buy as Stock Nears 52-Week High
Jefferies analyst Akash Tewari has reaffirmed a Buy rating on Eli Lilly and Company while lifting the price target from $1,330 to $1,350, signaling continued conviction in the pharma giant's growth trajectory. LLY shares are currently trading at $1,163.01, up 2.32% on the session, and sitting close to their 52-week high of $1,182.73. The stock has made a dramatic recovery from its 52-week low of $623.79, more than doubling over the past year to reclaim its position among the most valuable companies in the pharmaceutical sector.
Key Drivers of the LLY Stock Move
- Main Catalyst: Jefferies analyst Akash Tewari confirmed a Buy rating on LLY and raised the price target by $20, moving it from $1,330 to $1,350. The action reflects maintained bullish conviction with a modest upward revision to the firm's valuation outlook.
- Bull Case: The new $1,350 price target implies approximately 16% upside from the current price of $1,163.01. Combined with the stock's proximity to its 52-week high of $1,182.73, the Jefferies endorsement adds institutional support to what is already a technically strong setup.
- Bear Case: The price target increase of only $20 is relatively modest, suggesting Jefferies does not see dramatically accelerating upside from current levels. With LLY trading near its 52-week high, limited near-term technical room to the upside could weigh on momentum buyers looking for a larger risk-to-reward setup.
The Jefferies confirmation comes at a pivotal technical moment for LLY, with the stock trading within striking distance of its 52-week high. A clean breakout above $1,182.73 on sustained volume could open the door to price discovery toward the analyst consensus target. Eli Lilly has remained one of the most closely watched names in large-cap pharmaceuticals, driven by ongoing investor interest in its GLP-1 portfolio anchored by Mounjaro and Zepbound. Any further analyst upgrades or positive pipeline news could accelerate momentum heading into the second half of 2026, while a failure to clear the 52-week high could invite a consolidation phase before the next directional move.
LLY Analyst Ratings and Price Targets
Jefferies, through analyst Akash Tewari, confirmed its Buy rating on Eli Lilly on June 11, 2026, while raising the price target from $1,330 to $1,350. There were no upgrades or downgrades associated with this action. The consensus average price target across tracked analyst actions stands at $1,350, aligning directly with the Jefferies target and suggesting broad agreement on the stock's fair value ceiling among active coverage.
LLY Seasonality
Mid-June has historically been an active period for pharmaceutical re-ratings as analysts update models ahead of major medical conferences and mid-year portfolio reviews. For LLY specifically, positive analyst actions in this window have frequently coincided with building momentum into summer catalysts.
LLY Relative Performance
LLY's 2.32% gain on Thursday outpaces typical single-session moves for large-cap pharmaceutical peers and reflects strong relative strength within the sector. The stock's climb from its 52-week low of $623.79 to the current price of $1,163.01 represents a gain of roughly 86% over the trailing year, a performance that significantly exceeds broader healthcare sector averages and major index benchmarks over the same period.